Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Latent Membrane Protein-2a [LMP2A] Specific Eutil Autologous Blood-derived T Lymphocytes) in Patients With Progressive Epstein-Barr Virus (EBV) Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed

Trial Profile

A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Latent Membrane Protein-2a [LMP2A] Specific Eutil Autologous Blood-derived T Lymphocytes) in Patients With Progressive Epstein-Barr Virus (EBV) Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jan 2019

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top